Bristlecone Advisors, LLC Bristol Myers Squibb CO Transaction History

Bristlecone Advisors, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$47.98 - $54.4 $12,954 - $14,688	-270 Reduced 6.15%	4,117 $223,000
Q4 2023 Jan 25, 2024	SELL	$48.48 - $57.85 $23,755 - $28,346	-490 Reduced 10.05%	4,387 $225,000
Q3 2023 Oct 16, 2023	BUY	$57.89 - $64.73 $463 - $517	8 Added 0.16%	4,877 $283,000
Q2 2023 Aug 03, 2023	BUY	$63.71 - $70.74 $18,284 - $20,302	287 Added 6.26%	4,869 $311,000
Q1 2023 May 11, 2023	BUY	$65.71 - $74.53 $33,249 - $37,712	506 Added 12.41%	4,582 $317,000
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $410 - $486	6 Added 0.15%	4,076 $293,000
Q3 2022 Oct 27, 2022	SELL	$0.13 - $76.84 $6 - $4,072	-53 Reduced 1.29%	4,070 $289,000
Q2 2022 Jul 25, 2022	BUY	$72.62 - $79.98 $435 - $479	6 Added 0.15%	4,123 $317,000
Q1 2022 Apr 22, 2022	SELL	$61.48 - $73.72 $13,525 - $16,218	-220 Reduced 5.07%	4,117 $301,000
Q4 2021 Jan 19, 2022	BUY	$53.63 - $62.52 $375 - $437	7 Added 0.16%	4,337 $270,000
Q3 2021 Oct 19, 2021	BUY	$59.17 - $69.31 $47,336 - $55,448	800 Added 22.66%	4,330 $256,000
Q2 2021 Jul 21, 2021	BUY	$61.91 - $67.42 $2,785 - $3,033	45 Added 1.29%	3,530 $236,000
Q1 2021 Apr 30, 2021	BUY	$59.34 - $66.74 $206,799 - $232,588	3,485 New	3,485 $220,000
Q1 2020 Apr 16, 2020	SELL	$46.4 - $67.43 $424,142 - $616,377	-9,141 Closed	0 $0
Q4 2019 Jan 21, 2020	BUY	$49.21 - $64.19 $449,828 - $586,760	9,141 New	9,141 $587,000
Q3 2019 Oct 28, 2019	SELL	$42.77 - $50.71 $231,984 - $275,051	-5,424 Closed	0 $0
Q2 2019 Jul 19, 2019	BUY	$44.62 - $49.34 $242,018 - $267,620	5,424 New	5,424 $246,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Bristlecone Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Bristlecone Advisors, LLC with notifications on news.